ML 339

Pricing Availability   Qty

Save up to 40% on RUO Reagents with BIOSPRING24 (see details)

Description: Potent and selective hCXCR6 antagonist
Chemical Name: N-[(1R,3S,5S)-9-(2-((2-Chlorophenyl)amino)-2-exoethyl)-9-azabicyclo[3.3.1]nonan-3-yl)-3,4,5-trimethoxybenzamide
Purity: ≥98% (HPLC)
Literature (1)

Biological Activity for ML 339

ML 339 is a potent and selective hCXCR6 antagonist (IC50 = 140 nM); 100-fold less active at the murine CXCR6 receptor (IC50 = 18 μM). Exhibits selectivity over CXCR5, CXCR4, CCR6 and APJ receptors (IC50 >79 μM).

Compound Libraries for ML 339

ML 339 is also offered as part of the Tocriscreen 2.0 Max and Tocriscreen Antiviral Library. Find out more about compound libraries available from Tocris.

Technical Data for ML 339

M. Wt 502
Formula C26H32ClN3O5
Storage Store at +4°C
Purity ≥98% (HPLC)
CAS Number 2080300-49-6
PubChem ID 60202254
Smiles O=C(NC1=C(Cl)C=CC=C1)CN2[C@H]3CCC[C@@H]2C[C@](NC(C4=CC(OC)=C(OC)C(OC)=C4)=O)([H])C3

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for ML 339

Solvent Max Conc. mg/mL Max Conc. mM
DMSO 50.2 100
ethanol 10.04 20

Preparing Stock Solutions for ML 339

The following data is based on the product molecular weight 502. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.99 mL 9.96 mL 19.92 mL
5 mM 0.4 mL 1.99 mL 3.98 mL
10 mM 0.2 mL 1 mL 1.99 mL
50 mM 0.04 mL 0.2 mL 0.4 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

References for ML 339

References are publications that support the biological activity of the product.

Hershberger et al (2012) Probing the CXCR6/CXCL16 Axis: targeting prevention of prostate cancer metastasis. Probe Reports from the NIH Molecular Libraries Program PMID: 24049849

If you know of a relevant reference for ML 339, please let us know.

View Related Products by Target

View Related Products by Product Action

View all Chemokine CXC Receptor Antagonists

Keywords: ML 339, ML 339 supplier, ML339, Potent, human, CXCR6, antagonists, antagonism, metastasis, Chemokine, CXC, Receptors, 5943, Tocris Bioscience

Citations for ML 339

Citations are publications that use Tocris products.

Currently there are no citations for ML 339. Do you know of a great paper that uses ML 339 from Tocris? Please let us know.

Reviews for ML 339

There are currently no reviews for this product. Be the first to review ML 339 and earn rewards!

Have you used ML 339?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Rheumatoid Arthritis Poster

Rheumatoid Arthritis Poster

Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.